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Introduction 
 
Macrophages are mature myeloid cells, mostly 
derived from the differentiation of circulating 
monocytes after tissue infiltration. Far to be a 
homogeneous population, macrophages display 
a wide range of phenotypes and physiological 
properties depending on the cytokines inducing 
their maturation [1]. Moreover, macrophages 
are very plastic cells, able to switch from one 
functional sub-population to another depending 
on the stimulus received [2]. Another aspect of 
macrophage heterogeneity is the tissue speciali-
sation of resident macrophages, as microglial 
cells in the brain, Kupffer cells in the liver or 
alveolar macrophages in the lung. However, it is 
still not clear if these resident macrophages are 
derived in steady state condition from circulat-
ing monocytes and if they are terminally differ-
entiated cells [1]. After birth, macrophages are 
known to affect different stages of skin wound 
healing, modulating the function of the different 
cell types involved in this process. The benefit of 
inflammation and inflammatory cells in the 
wound healing is a matter of debate as in nor-
mal conditions it promotes wound closure but 
also the fibrosis associated with scar formation. 
Wound Associated Macrophages (WAM) have a 
central role in the control of wound inflamma-
tion. Here, we will present an overview of the 
main functions of WAM and their influence on 
the other major cell types present in the wound 
during the healing process and how modulating 
these processes might result in better wound 
healing.   
 
Wound healing  
 
In humans, and more widely in all mammalian 
species, the wound healing process can be sub-
divided in three consecutive and overlapping 
stages: inflammation, new tissue formation and 
remodelling [3]. The transition from one stage 
to another depends on the maturation and dif-
ferentiation of the main cell populations in-
volved, among which the keratinocytes, the fi-
broblasts and the macrophages. 
 
Inflammation 
 
The first event occurring after injury is the for-
mation of a blood clot by activated platelets. 
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The blood plug will be composed of various cell 
types including platelet, red and white blood 
cells. The initial plug is stabilised by fibrin fibres 
and will be a scaffold for the various infiltrating 
cells. The first inflammatory cells recruited are 
the neutrophils [4]. They infiltrate massively the 
wound during the first 24h post injury [5] at-
tracted by the numerous inflammatory cytokines 
produced by the activated platelets, endothelial 
cells, as well as by the degradation products 
from pathogens. Neutrophils enter apoptosis 
soon after infiltrating the wound and the release 
of cytokines during this apoptotic process is an 
important component in macrophage recruit-
ment. Macrophages infiltrate the wound mas-
sively 2 days post injury and exacerbate at this 
stage an intense phagocytic activity [6]. 
 
New tissue formation 
 
The reepithelialisation process begins few hours 
after the wound formation. Keratinocytes from 
the wound edges migrate over the wound bed at 
the interface between the wound dermis and 
the fibrin clot. This migration is facilitated by the 
production of specific proteases such as the 
collagenase by the epidermal cells to degrade 
the extracellular matrix [7]. Activated fibroblasts 
also migrate to the wound bed and form, with 
the macrophages, the granulation tissue. A 
massive angiogenesis allowing the supply of 
oxygen and nutrients necessary for the healing 
process also occurs within this tissue [8]. Later, 
some of the fibroblasts differentiate into myofi-
broblasts. These contractile cells will help 
bridge the gap between the wound edges [9]. 
During the same time, growth factors produced 
by the granulation tissue will favour proliferation 
and differentiation of epithelial cells restoring 
the epithelial barrier integrity.  
 
Remodelling 
 
The last stage of the wound healing process 
consists in a gradual involution of the granula-
tion tissue and dermal regeneration. This step is 
associated with the apoptosis of myofibroblasts, 
endothelial cells and macrophages. The remain-
ing tissue is therefore composed mostly of ex-
tracellular matrix proteins, essentially collagen 
type III that will be remodelled by the metallo-
proteinase produced by the epidermal cells, 
endothelial cells, fibroblasts and the macro-
phages remaining in the scar and be replaced 
by collagen type I [8]. 
Macrophages and wound healing 
 
Wound macrophage phenotypes 
 
Macrophages used to be divided in several sub-
populations depending of the way they had 
been activated, their cell surface markers or 
their functionality.  [1, 10,11]. Schematically, 
macrophages activated by microbial agents and 
cytokines like Interferon gamma (IFNγ) are clas-
sified as M1 macrophages. These macrophages 
produce an important level of Nitric Oxide (NO) 
and pro inflammatory cytokines such as Tumor 
Necrosis Factor alfa (TNFα), IL-1β, IL-6, or IL-12, 
and overexpress MHC class II molecules. They 
bear microbicidal and antitumoral properties.  
M2 macrophages are a much more heterogene-
ous population composed of all macrophages 
that do not correspond to M1 characteristics 
[12]. M2 macrophages could be divided in 3 
sub-populations. The alternatively activated 
macrophages or M2a, that promote a Th2 type 
of inflammation resulting in increased IgE as 
observed in allergy and parasite immunity, the 
M2b macrophages, that promote Th2 inflamma-
tion and bear some immunoregulation proper-
ties, and the deactivated macrophages or M2c, 
able to control the inflammation and implicated 
in tissue remodelling [12]. In another classifica-
tion, M1 macrophages are considered as the 
classically activated macrophages as compared 
to the alternatively activated macrophages. The 
best described alternative activation consists in 
the stimulation of the IL-4R by IL-4 and IL-13 
that induces pro Th2 macrophages [13]. Of 
course, all these sub populations should not be 
considered as distinct populations in vivo but 
more as different stages of a continuum of acti-
vation and differentiation of macrophage popu-
lations [14]. The phenotype of skin wound infil-
trating macrophages is not yet fully character-
ised, but it already appears that it changes dur-
ing the healing process suggesting that macro-
phages have different roles in the diverse 
phases of skin repair [15, 16].  
 
Several reviews refer to wound macrophages as 
the IL4 alternatively activated macrophages 
because of numerous markers of tissues re-
modelling, such as YM1, Resistin Like Molecule 
Alfa (RELMα), Insulin Growth Factor 1 (IGF1), 
factor XIII-A or arginase that are expressed after 
in vitro activation of macrophages with IL4. [13, 
17-20]. Recent work on aseptic wounds using 
an implantable sponge model described wound 
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macrophages as cells bearing both classical 
activation markers, like TNFα expression, and 
alternatively activated markers like the man-
nose receptor [15]. The authors also described 
the evolution of the macrophage phenotype. 
Day 1 macrophages produced more TNFα and 
IL6 and less Tumor Growth Factor beta (TGFβ) 
compared to day 7 macrophages suggesting a 
transition from an inflammatory to an immu-
noregulatory or tissue remodelling state. How-
ever, it is important to consider that neither IL4 
nor IL13 were detectable in this model, perhaps 
because of the aseptic experimental condition. 
However, it is not clear to what extent the bacte-
rial colonization of the wound would modify 
Wound Associated Macrophage phenotypes and 
healing functions, as it is clear that parasitic 
and bacterial component are major macro-
phage activators [13].  
 
Macrophage importance in wound healing 
 
In order to show the implication of macrophages 
in the control of wound healing, several studies 
have analysed skin wound healing upon macro-
phage depletion (Table 1). The first attempt con-
sisted in corticosteroids associated with anti 
macrophage sera to deplete macrophages in 
wounded guinea pigs. This treatment resulted in 
a delayed infiltration of the wound by fibroblasts 
and decreased fibrosis [6]. These results are in 
accordance with observations that fetal wounds 
heal without fibrosis and are not infiltrated by 
macrophages. In a model of PU.1 null mice 
where animals lacked macrophages, mast cells 
and functional neutrophils due to defective mye-
lopoiesis, wounds performed on newborns addi-
tionally treated with antibiotic healed at the 
same speed as wild types, but without scar for-
mation, suggesting that inflammatory cells are 
not needed for wound closure [21]. However, 
several recent models of specific inducible 
macrophage depletion, based on genetically 
modified mice resulted in detrimental effect of 
pre-injury depletion of macrophages [16, 22, 
23]. Mice depleted before injury typically show a 
defect in re-epithelisation, granulation tissue 
formation, angiogenesis, wound cytokine pro-
duction and myofibroblast associated wound 
contraction. Recently, the effect of a post-injury 
depletion of the WAM has also been investi-
gated. Macrophage depletion during the granu-
lation tissue formation, about 3 days after in-
jury, is associated with vascularisation defect, 
delay in wound closure as well as in granulation 
tissue maturation [16]. Finally, in their study, 
Lucas et al did not find any morphological or 
biological differences between mice that were 
or were not depleted 9 days after injury suggest-
ing no further implication of macrophages at 
later stages. 
 
During the healing process numerous cytokines 
and growth factors are produced by the various 
cell types present in the wound or at the wound 
edge [24]. The level of production of the differ-
ent cytokines depends on the regulation of the 
cross talk between the major cell populations in 
the wound: epithelial cells, endothelial cells, 
fibroblasts and inflammatory cells. However, the 
literature clearly lacks in vivo characterisation of 
the cytokine production kinetics by the various 
cell types during skin wound healing. Most of 
our current knowledge concerning the ability of 
a cell population to produce or to respond to a 
specific cytokine is based on in vitro studies. 
 
Cross talk with keratinocyte 
 
Injured and inflamed keratinocytes produce 
Table 1. Impact of macrophages depletion strategy on wound healing 
Depletion stage Depletion  
process 
Wound closure Gr T fromation / 
Angiogenesis 
Collagen / 
fibrosis/αSMA 
Ref 
Early Macrophage an-
tiserum 
↓ ND ↓ [6] 
Early CD11b DTR ↓ ↓ ↓ [22] 
Early lysM-Cre DTR ↓ ↓ ↓ [23] 
Early lysM-Cre DTR ↓ ↓ ↓ [16] 
Middle lysM-Cre DTR ↓ ↓ ND [16] 
Late lysM-Cre DTR = = = [16] 
Gr T: Granulation tissue 
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several cytokines allowing the recruitment and 
activation of the WAM, including chemokines, 
interleukins and growth factors [25, 26]. On the 
other hand, the ability of immune cells to pro-
duce factors able to regulate keratinocyte 
growth in vitro has been described since 1988 
[27]. Interestingly, conditioned medium from co-
culture of macrophages and allogenic T cells 
were much more efficient in inducing keratino-
cyte proliferation compared to conditioned me-
dium from macrophages alone. However, the 
direct implication of WAM in producing cyto-
kines or growth factors to influence directly or 
indirectly keratinocyte migration and prolifera-
tion is not clear in vivo. Several cytokines and 
growth factors, that can be produced by macro-
phages, have been associated with reepitheliali-
sation, mostly in vitro. Among the Epithelial 
growth Factor family (EGF), the main members 
involved in wound healing are EGF, TGFα and 
Heparin Bound EGF (EGF-HB) [28-32]. The acti-
vation of the EGF Receptor (EGFR) on keratino-
cytes promotes cell migration and proliferation. 
Although, only TGFα and EGF-HB have been 
described to be produced by macrophages in 
vitro, their production by WAM in vivo is more 
enigmatic [33, 34]. TGFα has been detected in 
macrophages collected from sub epidermal 
wound cylinders 6 days after implantation in 
mice [35]. However, no significant wound heal-
ing abnormalities were observed in TGFα-/- 
mice [36]. In addition, all EGFR ligands are syn-
thetised as membrane-anchored forms, which 
can be released as a soluble form after prote-
olysis by MMP [37]. Therefore, another possible 
role for WAM might be the regulation of EGF 
family release by the production of MMPs. Other 
cytokines as IL-6, IL1 and TNF-α produced by 
macrophages are also associated with reepi-
thelisation. Even if the secretion of these cyto-
kines by WAM has not been clearly demon-
strated yet, the ability of macrophages activated 
by the inflammatory cytokine IFNγ and/or bacte-
rial products via Toll Like Receptor 4 (TLR4) to 
produce IL-6, IL1β and TNFα makes this hy-
pothesis probable [13]. The implication of IL-1 
and IL-6 in the reepithelialisation is indirect and 
is mediated by other cell types present in the 
wound, at least the fibroblast [38, 39]. On the 
contrary, TNFα directly stimulates transcription 
of genes associated with numerous cell func-
tions including inflammation, mobility, cell divi-
sion and survival in keratinocytes [25]. Of note, 
in a model of sponge implanted under aseptic 
conditions in the dermis, macrophages ex-
tracted on day 1 produced more TNFα com-
pared to day 7 [15]. Finally, the other cytokine 
known to be massively produced by macro-
phages, and highly implicated in reepithelialisa-
tion, is TGFβ, although its effect on keratinocyte 
proliferation and migration remains controver-
sial [36, 40-43]. Cultured WAM extracted from 
implanted sponges start producing TGFβ from 
the very first day of the wound [15].  
 
Influence on fibroblasts and myofibroblast 
 
Fibroblasts begin to infiltrate the wound during 
the first steps of granulation tissue formation. 
Fibroblasts are involved in several processes of 
the wound healing. They contribute to the 
granulation tissue formation, produce the cyto-
kines that favour keratinocyte proliferation and 
migration [44], and finally  differentiate in myofi-
broblasts to promote wound closure. Several 
molecules, such as PDGF-bb, TNFα, IL-1 or IL-6, 
produced by activated macrophages are able to 
induce in vitro the production of pro-
reepithelialisation molecules by fibroblasts such 
as KGF [45-48]. Interestingly, the effect of most 
of these molecules is dependent on the pres-
ence of serum in the fibroblast culture media, 
indicating that the stimulation resulting in their 
production is a cooperative process [49]. Mori 
et al demonstrated nicely that macrophage se-
cretion of PDGF-bb isoform induced the produc-
tion of osteopontin by fibroblasts [50]. The inhi-
bition of osteopontin was associated with lower 
scar fibrosis [50]. Finally, the molecule pro-
duced by macrophages that has been the most 
extensively studied for its actions on wound 
fibroblasts is TGFβ. It is a family of three cyto-
kines, TGFβ1, 2 and 3, produced by several cell 
types during the healing process, including 
platelets and epidermal cells, but the main and 
sustained source of production are the WAM 
[16, 51]. All TGFβ family members are secreted 
coupled to a “latent complex” which has the 
ability to bind the Extra Cellular Matrix (ECM). 
The latent forms have to be activated via vari-
ous mechanisms to release the mature TGFβ, 
including proteolysis by MMPs known to be ex-
tensively secreted by macrophages as reviewed 
by Annes et al [52]. While TGFβ1 and 2 promote 
the inflammation within the wound and are as-
sociated with scar formation, TGFβ3 is associ-
ated with scar free wound healing [53]. How-
ever, the expression of TGFβ3 in adult wound is 
rare while the two other forms are highly ex-
pressed [53]. TGFβ1 is chemotactic for fibro-
Skin wound healing modulation by macrophages  
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blasts [54, 55]. It induces the production of sev-
eral growths factors by fibroblasts, including 
Connective Tissue Growth Factor (CTGF) [56], 
that results in their proliferation by an autocrine 
loop [57]. But the main action of TGFβ on fibro-
blast is to promote their differentiation into myo-
fibroblast and to favour collagen production 
[58]. The secretion of TGFβ and MMP by the 
macrophages is critical in the control of the 
ECM composition. Accordingly, macrophage 
depletion is associated with a defect of Alpha 
Smouth Muscle Actin (αSMA) positive cell in the 
granulation tissue [23]. However, it is estimated 
that 30 to 50% of the granulation tissue αSMA+ 
cells do not derive from fibroblasts, but more 
likely from bone marrow derived fibrocytes or 
mesenchymal stem cells [59-61]. The implica-
tion of macrophage produced cytokines in the 
recruitment, activation and differentiation of 
these marrow derived fibrocytes in the wound 
bed is unknown and has to be further investi-
gated.  
 
Cross talk with endothelial cell 
 
Neo-angiogenesis in the granulation tissue is an 
important process allowing the supply of nutri-
ents necessary for the healing process. The 
main angiogenic factor in the wound is the Vas-
cular Endothelial Growth Factor (VEGF) and its 
reduced expression results in a wound healing 
defect [62]. VEGF promotes wound vascularisa-
tion by multiple mechanisms targeting directly 
or indirectly endothelial cells as reviewed by 
Eming et al [63]. VEGF promotes endothelial 
cell and precursor recruitment [64] but it also 
acts as a mitogen and survival factor on the 
endothelial cells [65-67]. The increase of VEGF 
production in the wound is described in migra-
tory keratinocytes and in macrophages infiltrat-
ing the granulation tissue [62]. The keratinocyte 
production of VEGF is indirectly promoted by 
macrophages as well through the secretion of 
cytokines as TNFα or TGFβ [68]. CTGF produced 
by fibroblasts [56], also favours endothelial cell 
proliferation and new vessel formation [69, 70]. 
VEGF family members, mostly VEGF-C and VEGF
-D, have also been recognized for their ability to 
modulate lymphangiogenesis [71]. Decreased 
macrophage numbers and activation has been 
associated with reduced lymphatic vessel for-
mation in diabetic mouse wounds [72]. It is im-
portant to note that double positive F4/80/Lyve
-1 cells have been described to be integrated in 
lymphatic vessels in several models of neo-
lymphangiogenesis suggesting that macro-
phages could be directly implicated in their for-
mation [72, 73]. 
 
The other main pro-antigenic molecule during 
the wound healing is the Placental Growth Fac-
tor (PlGF), a member of the VEGF family [67] 
[74]. PlGF expression is induced in vitro by TGFα 
and TGFβ, and is produced during the angio-
genic stage of the healing process [75]. The 
effects of PlGF are similar to those of VEGF, 
promoting monocytes and endothelial precursor 
cell migration [76] and favouring endothelial 
Table 2. Targeting of macrophages to  control healing of pathological wound 
Molecules / 
cells 
Delivery Stage Pathological 
model 
Wound 
model 
Effect on MΦ Effect  on 
healing 
Ref 
MALP-2 local Early to 
middle 
Diabetic 
C57Bl6 db/db 
Acute ↑ recruitment ↑ [89] 
GM-CSF local NA Human CVLU Chronic ↑ VEGF pro-
duction 
↑ [88] 
Anti TNFα Systemic Early to 
late 
Diabetic 
ob/ob 
Acute ↓ recruitment ↑ [90] 
IL1β acti-
vated db/db 
MΦ 
Local Early Diabetic 
C57Bl6 db/db 
Acute  ↑ 
VEGFC/
VEGFR3 tran-
scription 
↑ [72] 
GM-CSF local Early Strpz induce 
diabetic mice 
Acute ↑ Recruit-
ment 
↑ [86] 
CVLU: Chronic Veinous Leg Ulcer. Strpz : streptozotocin 
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cell survival [77]. PlGF stimulates also the se-
cretion of VEGF by the monocyte/macrophages 
[78]. Interestingly, even if PlGF is described to 
have chemotactic properties by his own on 
VEGFR1+ expressing cells, the synergy between 
PlGF and VEGF is important in angiogenesis 
[79]: i) VEGFR1 homodimers may be a decoy 
receptor. Binding of PlGF homodimer to VEGFR1 
homodimer make more VEGF available to bind 
to activated VEGFR2. ii) VEGF/PlGF het-
erodimers bind to VEGFR1/VEGFR2 het-
erodimer and induce more potent angiogenic 
signals iii) binding of PlGF homodimers to 
VEGFR1 homodimers favours VEGFR2 
homodimer phosphorylation [80]. Overall, PlGF 
seems to potentiate the effect of VEGF in wound 
angiogenesis. These results altogether point to 
the important role of macrophages in coordinat-
ing the angiogenic signal during wound healing. 
 
Macrophages and defective wound healing 
 
Despite their heterogeneous aetiology, most 
chronic wounds have in common a defect in the 
progression from the inflammatory to the tissue 
formation stage. Loots et al reported increased 
infiltration of chronic and diabetic wounds by 
WAM compared to control acute wounds. In 
addition they observed higher amounts of ECM 
in the wound edge [81]. Similarly, in diabetic 
db/db mice, wounds are characterising by a 
prolonged expression of inflammatory cytokines 
and larger infiltration and persistence of the 
WAM [82]. However, these cells seem to have 
altered sensitivity towards exogenous signals 
such as VEGF or IGF1 [83, 84] as well as al-
tered ability to release cytokine [85]. Several 
studies have targeted macrophages, by differ-
ent strategies in order to improve defective 
wound healing (Table 2). In the obese diabetic 
Figure 1. Direct and indirect control of reepithelialisation, angiogenesis and fibroblast activation by macrophages. 
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db/db mouse model, the injection of peritoneal 
macrophages activated by IL-1β at the wound 
site was associated with an increased produc-
tion of prolymphangiogenic molecules such as 
VEGF-C, resulting in improved lymphangiogene-
sis and wound healing [72]. Local application of 
GM-CSF is associated with better healing both 
in human and mouse pathological wounds in a 
clinical setting. In Streptozotocin induced dia-
betic mice, GM-CSF is associated with a 
stronger infiltration of the wound by macro-
phages, increased angiogenesis and a better 
healing, while no effect was observed in normal 
wound healing [86] [87]. Similarly, in a pilot 
study in humans, GM-CSF treatment improves 
chronic vascular ulcers, probably by promoting 
the secretion of VEGF by macrophages [88]. 
With a similar strategy, Deiters et al injected 
Macrophage-Activating Lipopeptide-2 (MALP-2) 
in wounds on obese diabetic db/db mice. MALP-
2 induced the transcription of several genes 
associated with wound healing, including GM-
CSF and IL-1 [89] and resulted in increased 
infiltration by WAM and more rapid wound clo-
sure. In opposition to these activating ap-
proaches, Goren et al used a depleting strategy 
based on the systemic injection of a neutralizing 
anti-TNFα in ob/ob mice [90]. The treatment 
resulted in a systemic and local depletion of 
macrophages that was associated with a faster 
healing. Taken together, these results sustain 
the hypothesis that in chronic or diabetic 
wounds different strategies that might affect 
macrophage phenotype might modify the heal-
ing. 
 
Conclusions 
 
Our current knowledge points to macrophages 
as key players in skin wound healing after birth. 
Healing is a complex and evolving process, and 
because of their plasticity, WAM progress with 
the wound, adapting their cytokine expression 
profile [15]. Because of this plasticity and of 
their central position, WAM seem to be the ideal 
target for clinical interventions in chronic 
wounds, to accelerate closure or to attenuate 
fibrosis (Figure 1). For this purpose, there is still 
a need to further characterise this population. It 
seems obvious that, similar to other inflamma-
tion models, WAM are essentially composed of 
infiltrating blood monocytes that change from 
an inflammatory phenotype to a repair one [15, 
91, 92]. It is not clear if the multiple functions 
of WAM are exclusive to a unique macrophage 
population or fulfilled by specialised sub popula-
tions at different time points? Should the future 
therapeutic strategies consist in the control of 
the WAM polarisation or in the specific recruit-
ment or depletion of sub populations? These 
strategies will also have to define the appropri-
ate timing for their effectiveness as WAM bear 
different functions during the healing time 
course [16].  
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